Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO , Oct. 13, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned